Abstract:Abstract Abstract 3054 Background: Disease relapse, major infection and graft-versus-host disease (GVHD) are the leading causes of death following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Donor T lymphocytes play a critical role in alloimmune recognition and their ability to detect non-self-antigens can lead to GVHD or contribute to prevention of relapse and infection. Three effector pathways have been described for T-cell cytotoxicity: granzyme B/perforin, Fas/Fas ligand (FasL) and secreted molecules such as tumor necrosis factor (TNF)-alpha. Granzyme B is a proapoptotic serine protease. Fas is widely expressed in immunocompetent cells and non-lymphoid tissues. FasL is mainly expressed on activated cytotoxic T lymphocytes (CTLs). When CTLs recognize target cells, they become activated and express FasL which induces apoptosis of target cells. The Fas gene has been found to be silenced in many tumor types. The importance of those effector pathways for the development of acute GVHD (aGVHD) has been well established. In our previous study, we have reported donor and/or recipient TNF-alpha gene polymorphism influenced on the risk of aGVHD. Recently several important polymorphisms have been identified in granzyme B, Fas, and FasL genes and reported to be relevant to allograft rejection in solid organ transplant patients. However, such information is less available in allo-HSCT. This present study was designed to investigate the influence of donor and recipient genetic variations of effector pathway molecules on the abilities of T-cell alloimmune responses including GVHD, cytomegalovirus (CMV) infection within 100 days and disease relapse following allo-HSCT. Methods: The entire study population consisted of 138 pairs of recipients and their unrelated donors, who underwent HSCT in our Center from January 2001 to March 2009. Genomic DNA was extracted from peripheral blood samples obtained from recipients and donors before transplantation. Five single nucleotide polymorphisms (SNPs) including granzyme B +55(A/G), -295(C/T), Fas -1377(G/A), -670(T/C) and FasL -844 (T/C) were analyzed. Results: (1) Patients receiving stem cells from a donor with granzyme B +55 AA genotype developed aGVHD more frequently than those with mutated allele (AG or GG), which has been reported to be associated with low-producing of granzyme B by CTLs and incapable of inducing apoptosis. Multivariate analysis confirmed that donor with the granzyme B +55 AA genotype was an independent risk factor for aGVHD (RR=1.545, 95%CI: 1.012–2.357, P=0.044). (2) Donor with FasL -844 TT genotype, a genotype reported to a reduction in the expression of FasL on T cells, conferred protection against the risk of aGVHD (RR=2.981, 95% CI: 1.320–6.736, P=0.009), however was an independent risk factor for early CMV infection (RR: 3.658, 95% CI: 1.534–8.722, P=0.003). Patients experiencing aGVHD have a higher risk of developing early CMV infection (RR=1.931, 95% CI: 1.242–3.003, P=0.003), early CMV infection also was a significant factor impacting aGVHD (RR=1.630, 95%CI: 1.294–2.053, P<0.001). (3) Recipient with Fas -670 C- allele positive, a mutated allele with higher Fas expression, was associated with a significantly lower risk of relapse (RR=3.453, 95% CI: 1.699–7.091, P=0.001) as well as superior overall survival (84.2% vs 21.2%, P<0.001) in patients with acute myeloid leukemia (AML), but not in patients with other myelogenous or lymphoid malignancies. The polymorphic sites granzyme B -295(C/T), Fas -1377(G/A), did not correlate with the T-cell alloimmune reactivities. Conclusions: Genetic variation, other than HLA polymorphism, regulating the immune response may influence outcomes of patients undergoing allo-HSCT. Transplant patients would thus benefit from accurate risk assessment and individualization of immunosuppressive therapy, taking into account donor and recipient genetic data, as well as other risk factors. This study is the first report of relationship between donor or recipient genetic variations of effector pathway molecules and the abilities of T-cell alloimmune responses. According to our results, special targeting granzyme B and Fas/FasL pathways may be a promising therapeutic strategy in patients with aGVHD, CMV infection and leukemia relapse after allo-HSCT at least in AML patients harboring Fas -670 wild-type genotype. Disclosures: No relevant conflicts of interest to declare.

Recipient APOL1 Risk Alleles Associate with Death-Censored Renal Allograft Survival and Rejection Episodes

Genetic Variation In The Effector Pathways Of Cytotoxic T Lymphocytes Influences Alloimmune Reactivities Following Allogeneic Hematopoietic Stem Cell Transplantation

Donor Inflammatory Gene Polymorphisms Are Associated With Early Bacterial Infection After Unrelated Allogeneic Haematopoietic Stem Cell Transplantation.

Genetic polymorphisms of Leukocyte Immunoglobulin-Like Receptor B3 (LILRB3) gene in African American kidney transplant recipients are associated with post-transplant graft failure

APOL1 risk variants, race, and progression of chronic kidney disease

Strong protective effect of the APOL1 p.N264K variant against G2-associated focal segmental glomerulosclerosis and kidney disease

ANALYSIS OF GLOMERULAR TRANSCRIPTOMES FROM NEPHROTIC PATIENTS SUGGEST APOL1 RISK VARIANTS IMPACT PARIETAL EPITHELIAL CELLS

Genetic Inhibition of APOL1 Pore-Forming Function Prevents APOL1-Mediated Kidney Disease

Protein-truncating variant in APOL3 increases chronic kidney disease risk in epistasis with APOL1 risk alleles

Genome-wide non-HLA donor-recipient genetic differences influence renal allograft survival via early allograft fibrosis

#3155 APOL1 GENOTYPE IS A MAJOR DETERMINANT OF LUPUS NEPHRITIS SEVERITY IN PATIENTS OF AFRICAN ANCESTRY

SMOC2 gene interacts with APOL1 in the development of end-stage kidney disease: A genome-wide association study

APOL1-mediated monovalent cation transport contributes to APOL1-mediated podocytopathy in kidney disease

APOL1 nephropathy – a population genetics success story

Epigenetic associations with kidney disease in individuals of African ancestry with APOL1 high-risk genotypes and Human Immunodeficiency Virus

APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases

APOL1 Kidney Risk Variants and Proteomics

Evaluating ApoL1 Genetic Testing Policy Options for Transplant Centers

APOL1 promotes endothelial cell activation beyond the glomerulus

Apolipoprotein L1 (APOL1) renal risk variant-mediated podocyte cytotoxicity depends on African haplotype and surface expression

High Serum Level of the Soluble CD30 Identifies Chinese Kidney Transplant Recipients at High Risk of Unfavorable Outcome